AIDS Meds: Founded & Operated by People with HIVPOZ logo
Back to home » Treatment News » Top Stories

emailrssprint

Tenofovir Prodrug Delays SHIV Infection

October 10, 2006

(Reuters Health) - October 10, 2006 (Reuters Health)—Tenofovir disoproxil fumarate (TDF), the oral prodrug of tenofovir, provides some protection to macaques repeatedly challenged with simian human immunodeficiency virus (SHIV), researchers report. The findings hint that pre-exposure prophylaxis against HIV might be possible.

As senior researcher Dr. Thomas Folks told Reuters Health, "the recent work showing a delay in mucosal SHIV infection in adult monkeys gives a first glimpse of partially successful pre-exposure prophylaxis (PrEP) with an oral drug and provides some guidance for PrEP studies in future human clinical trials."

As reported in the October 1st issue of the Journal of Infectious Diseases, Dr. Folks of the Centers for Disease Control and Prevention, Atlanta, and colleagues inoculated 12 male Chinese rhesus macaques intrarectally with SHIV.

These doses, which were about 5 times higher than HIV levels in human semen noted during acute infection, were repeated weekly for up to 14 weeks or until the animals became infected.

Four animals received daily oral TDF starting some hours after the SHIV injection, another four did so once weekly and the remaining 4 animals acted as controls.

Control animals became infected after a median of 1.5 inoculations. Those given the daily dose of TDF became infected at a median of 6 weeks, although one animal remained uninfected at 14 weeks. The corresponding interval in those given the weekly dose was 7 weeks.

These differences were not significant. However, the researchers point out the study was limited by the small numbers of animals involved and the variable blood levels of TDF resulting from oral dosing.

In an accompanying editorial, Drs. Mark A. Wainberg of McGill University, Montreal and Robert M. Grant of the University of California, San Francisco, note that clinical trials of TDF PrEP have already achieved "substantial enrollment." These trials will help evaluate whether TDF alone is sufficient in humans, although, they say "this approach was only partially effective for animals."



Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

emailrssprint



[Go to top]



Most Popular Stories

CD4s Predictive of Non-AIDS-Related Health Problems

HIV Immunotherapy Shows Promise

Slim for Summer: Safe and Sane Weight Loss

Hetero Men Also at Risk for Anal HPV

Treatment Failure: Symptoms Matter Too

Interfering with Immune Protein Slows HIV Reproduction


Most Popular Lessons

Herpes Simplex Virus

Syphilis & Neurosyphilis

Shingles

The HIV Life Cycle

Human Papilloma Virus (HPV)

What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Treatment News Archive

May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006


© 2008 Smart + Strong. All Rights Reserved. terms of use and your privacy